The 6th RNA Editing Summit returns to Boston this July, bringing together 60+ experts to propel the next generation of RNA editing therapies for rare and common diseases. With momentum building from ...

Blood test analyses cell-free RNA to detect cancers, treatment resistance, and tissue injury, offering a powerful new tool ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, ...

This small branch played a big role in advancing evidence-based genetic testing, and its loss diminishes US leadership in ...

Integrated DNA Technologies unveils xGen Hybridization and Wash v3 Kit, a newly designed target enrichment solution to ...

The following is a summary of "Prediction of radiosensitivity in non-small cell lung cancer based on computed tomography and tumor genomics: a multiple real-world cohort study," published in the April ...

BostonGene, a leader in AI-driven molecular and immune profiling that accelerates drug development and personalizes patient care, today announced that four abstracts have been selected for ...

Cell crowding causes high-grade breast cancer cells to become more invasive by activating a molecular switch that causes the cells to shrink and spread.

As previously reported, BTIG initiated coverage of Tempus AI (TEM) with a Buy rating and $60 price target Tempus AI is a rapidly growing ...